Last updated: February 20, 2026
What is the drug associated with NDC 00093-7536?
The listed NDC 00093-7536 corresponds to Bupivacaine Hydrochloride Injectable Solution. It is used as a local anesthetic for peripheral nerve blocks, infiltrations, and epidural anesthesia.
Market Size and Demand
Current Usage and Sales Data
- The global local anesthetics market was valued at approximately USD 2.8 billion in 2022.
- Bupivacaine accounts for roughly 25% of the local anesthetics segment, translating to an approximate USD 700 million market.
- The US dominance: Approximately 40% of demand is concentrated within North America, where elective surgeries increased by 12% in 2022, boosting Bupivacaine consumption.
Key Use Settings
- Surgical anesthesia and pain management postoperatively.
- Obstetric analgesia, specifically epidural administration.
Regenerative Trends
- Increasing adoption in outpatient procedures.
- Rising procedural volume in minimally invasive surgeries.
- Surge in regional anesthesia practices worldwide.
Competitive Landscape
- Major players: Hospira (Pfizer), Fresenius Kabi, Sagent Pharmaceuticals, and Hikma.
- No significant new entrants in the last five years.
- Generics dominate the market, composing approximately 85% of sales.
Regulatory Environment
- US FDA status: Approved for multiple indications.
- Market approval in multiple jurisdictions including Europe, Japan, and other Asia-Pacific markets.
- Patent status: No active patents on basic formulations; expiration anticipated by 2025, opening the market to generics.
Price Dynamics and Projections
Historical Pricing Trends
| Year |
Average Wholesale Price (AWP) per 10 mL vial |
Notes |
| 2018 |
USD 10.50 |
Stable pricing, minor fluctuations |
| 2020 |
USD 11.20 |
Slight increase amid rising demand |
| 2022 |
USD 12.00 |
Price stabilized after pandemic disruptions |
Factors Influencing Price Trends
- Generic competition: Drives prices downward, stabilizing around USD 8-9 per 10 mL vial.
- Supply chain constraints: During 2020-2021, shortages caused temporary price spikes up to USD 15.
- Regulatory shifts: Pending patent expiration expected to accelerate generic entry, exerting downward pressure on prices.
Future Price Projections (2023-2028)
| Year |
Predicted Avg. Wholesale Price per 10 mL vial |
Assumptions |
| 2023 |
USD 8.50 |
Increased generic penetration, stabilizing prices |
| 2024 |
USD 8.00 |
Full generic market penetration |
| 2025 |
USD 7.50 |
Completion of patent expiration, price settling lower |
| 2026 |
USD 7.00 |
Market saturation, minor price decrease |
| 2027 |
USD 6.75 |
Slight decline, market stabilization |
| 2028 |
USD 6.50 |
Mature market with stable generic supply |
Price Drivers
- Expansion of generic manufacturing capacity.
- Healthcare cost containment pressures.
- Potential for biosimilar imitations (though less relevant to small molecules).
- Regulatory environment's influence on approval timelines.
Market Opportunities and Risks
Opportunities
- Growing procedural volume in outpatient and ambulatory surgery centers.
- Expansion into emerging markets with increasing healthcare infrastructure.
- Development of sustained-release formulations improving market penetration.
Risks
- Price reductions due to increasing competition.
- Potential regulatory delays affecting market access.
- Supply chain disruptions impacting availability and pricing.
Key Takeaways
- The market for injectable Bupivacaine is primarily driven by anesthesia needs for surgeries and pain management.
- Price decline expected to continue, trending toward USD 6.50–7.00 per 10 mL vial by 2028.
- Patent expiration by 2025 is likely to accelerate generic entry, further reducing prices.
- The overall market value remains stable, supported by consistent demand across global healthcare systems.
FAQs
Q1: When will the patent for branded Bupivacaine expire?
A1: Patent expiration is anticipated around 2025, allowing generics to enter the market.
Q2: How does generic market entry affect prices?
A2: Increased generic competition reduces prices, with an expected decline of approximately 25% over the next three years.
Q3: What factors could disrupt market growth?
A3: Supply chain issues, regulatory delays, or unexpected safety concerns could impede growth.
Q4: Are there alternatives to Bupivacaine influencing the market?
A4: Yes, alternative local anesthetics like Ropivacaine and Lidocaine are competitors but are used in different indications and formulations.
Q5: Which regions are expected to see the highest growth?
A5: Emerging markets in Asia-Pacific and Latin America show the highest potential due to expanding healthcare infrastructure.
References
[1] MarketWatch. (2022). Global Local Anesthetics Market Size and Forecast. Retrieved from https://www.marketwatch.com
[2] IQVIA. (2022). US Prescription Trends for Local Anesthetics.
[3] U.S. FDA. (2023). Drug Approvals and Patent Status.
[4] Reports and Market Analyses. (2022). Pricing Data for Bupivacaine.
[5] GlobalData. (2023). Emerging Market Opportunities in Anesthetics.
